ORGENESIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5071 USD | +0.62% |
|
+1.24% | +1.28% |
| 04-16 | North American Morning Briefing : Powell Comments, -2- | DJ |
| 04-15 | Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 36.02M 2.88B | Sales 2023 | 530K 42.4M | Capitalization | 15.96M 1.28B |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.12B | Net income 2023 | -55M -4.4B | EV / Sales 2022 | 1.8 x |
| Net Debt 2022 | 14.96M 1.2B | Net Debt 2023 | 21.78M 1.74B | EV / Sales 2023 | 71.2 x |
| P/E ratio 2022 |
-3.29
x | P/E ratio 2023 |
-0.26
x | Employees | 146 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orgenesis Inc.
More press releases
| 1 day | +0.62% | ||
| 1 week | +1.24% | ||
| Current month | -38.31% | ||
| 1 month | -38.31% | ||
| 3 months | +63.32% | ||
| 6 months | -44.79% | ||
| Current year | +1.28% |
1 week
0.49
0.52
1 month
0.300.88
Current year
0.250.91
1 year
0.251.50
3 years
0.256.47
5 years
0.258.30
10 years
0.2516.80
| Managers | Title | Age | Since |
|---|---|---|---|
Sarah Ferber
FOU | Founder | 70 | 04/06/08 |
Vered Caplan
CEO | Chief Executive Officer | 55 | 01/02/12 |
Victor Miller
DFI | Director of Finance/CFO | 54 | 01-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Sidransky
BRD | Director/Board Member | 64 | 17/07/13 |
Vered Caplan
CEO | Chief Executive Officer | 55 | 01/02/12 |
Mario Philips
BRD | Director/Board Member | 54 | 08/01/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.5071 | +0.62% | 24,517 |
| 25/04/24 | 0.504 | +0.40% | 11,934 |
| 24/04/24 | 0.502 | -3.28% | 35,608 |
| 23/04/24 | 0.519 | +2.33% | 18,415 |
| 22/04/24 | 0.5072 | +1.26% | 22,024 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Companyâs therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomeraâs services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.28% | 17.27M | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- ORGS Stock
